Exhibit 99.2

FOAMIX PHARMACEUTICALS LTD.

UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS

AS OF JUNE 30, 2016

FOAMIX PHARMACEUTICALS LTD.

UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS

AS OF JUNE 30, 2016

INDEX

	Page
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:
Balance sheets	2-3
Statements of operations	4
Statements of comprehensive loss	5
Statements of changes in shareholders' equity	6
Statements of cash flows	7
Notes to financial statements	8-17

The amounts are stated in US dollars in thousands (except for share data)

FOAMIX PHARMACEUTICALS LTD.

CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands)

(Unaudited)

	June 30,		December 31,
	2016		2015
A s s e t s
CURRENT ASSETS:
Cash and cash equivalents	$	20,006	$	18,795
Short term bank deposits		28,123		13,107
Investment in marketable securities (Note 4)		27,203		23,693
Restricted investment in marketable securities (Notes 3,6)		954		769
Accounts receivable:
Trade		754		314
Other		373		471
TOTAL CURRENT ASSETS		77,413		57,149

NON-CURRENT ASSETS:
Investment in marketable securities (Note 4)		14,600		32,285
Investment in long term bank deposits		-		15,130
Property and equipment, net		796		646
Other		35		35
TOTAL NON-CURRENT ASSETS		15,431		48,096

TOTAL ASSETS	$	92,844	$	105,245

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

FOAMIX PHARMACEUTICALS LTD.

CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands)

(Unaudited)

	June 30,			December 31,
	2016			2015
Liabilities and shareholders’ equity

CURRENT LIABILITIES:
Current maturities of bank borrowing	$	32		$	31
Accounts payable and accruals:
Trade		1,342			1,353
Deferred revenues		-			29
Other		1,571			2,169
Loan from the BIRD foundation		-			476
TOTAL CURRENT LIABILITIES		2,945			4,058

LONG-TERM LIABILITIES:
Bank borrowing		4			20
Liability for employee severance benefits		379			365
TOTAL LONG-TERM LIABILITIES		383			385
TOTAL LIABILITIES		3,328			4,443
COMMITMENTS (Note 6)
SHAREHOLDERS' EQUITY:
Ordinary Shares, NIS 0.16 par value - authorized: 50,000,000 Ordinary Shares as of June 30, 2016 and December 31, 2015; issued and outstanding: 30,661,632 and 30,639,134 Ordinary Shares as of June 30, 2016 and December 31, 2015, respectively		1,285			1,284
Additional paid-in capital		147,107			145,878
Accumulated deficit		(58,931	)		(46,230	)
Accumulated other comprehensive income (loss)		55			(130	)
TOTAL SHAREHOLDERS' EQUITY		89,516			100,802
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	92,844		$	105,245

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

FOAMIX PHARMACEUTICALS LTD.

CONSOLIDATED STATEMENTS OF OPERATIONS

(U.S. dollars in thousands, except per share data)

(Unaudited)

	Six months ended June 30						Three months ended June 30
	2016			2015			2016		2015
REVENUES (Note 8)	$	1,497		$	557		$	752	$	109
COST OF REVENUES		43			36			12		13
GROSS PROFIT		1,454			521			740		96
OPERATING EXPENSES:
Research and development		10,300			4,915			6,734		2,795
Selling, general and administrative		3,838			3,395			2,128		2,023
TOTAL OPERATING EXPENSES		14,138			8,310			8,862		4,818
OPERATING LOSS		12,684			7,789			8,122		4,722
FINANCE EXPENSES (INCOME), net		(160	)		(66	)		14		(83	)
LOSS BEFORE INCOME TAX		12,524			7,723			8,136		4,639
INCOME TAX		177			9			57		8
NET LOSS FOR THE PERIOD	$	12,701		$	7,732		$	8,193	$	4,647

LOSS PER SHARE BASIC AND DILUTED	$	0.41		$	0.30		$	0.27	$	0.18

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE IN THOUSANDS		30,658			25,837			30,661		25,917

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

FOAMIX PHARMACEUTICALS LTD.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(U.S. dollars in thousands)

(Unaudited)

	Six months ended June 30						Three months ended June 30
	2016			2015			2016			2015
NET LOSS	$	12,701		$	7,732		$	8,193		$	4,647
OTHER COMPREHENSIVE INCOME:
Net unrealized gains from marketable securities		(167	)		(18	)		(11	)		-
Gains (losses) on marketable securities reclassified into net loss		4			(67	)		2			-
Net unrealized losses (gains) on derivative financial instruments		(26	)		(58	)		52			(73	)
Gains on derivative financial instruments reclassified into net loss		4			-			-			-
TOTAL OTHER COMPREHENSIVE LOSS (INCOME)		(185	)		(143	)		43			(73	)
TOTAL COMPREHENSIVE LOSS	$	12,516		$	7,589		$	8,236		$	4,574

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

FOAMIX PHARMACEUTICALS LTD.

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
(U.S. dollars in thousands, except share data)

(Unaudited)

	Ordinary shares				Additional paid-incapital			Accumulated deficit			Accumulated other comprehensive income (loss)			Total
	Number of shares		Amounts		Amounts
BALANCE AS OF JANUARY 1, 2015		22,443,934	$	954	$	77,600		$	(29,713	)	$	(79	)	$	48,762
CHANGES DURING THE SIX MONTHS ENDED JUNE 30, 2015:
Comprehensive loss									(7,732	)		143			(7,589	)
Issuance of Ordinary Shares through a public offering, net of $4,818 issuance costs (Note 5a)		7,419,353		298		63,904									64,202
Exercise of warrants		515,634		21		2,109									2,130
Exercise of options		163,850		7		308									315
Share-based compensation (Note 5c)						859									859
BALANCE AT JUNE 30, 2015		30,542,771	$	1,280	$	144,780		$	(37,445	)	$	64		$	108,679

BALANCE AS OF JANUARY 1, 2016		30,639,134	$	1,284	$	145,878		$	(46,230	)	$	(130	)	$	100,802
CHANGES DURING THE SIX MONTHS ENDED JUNE 30, 2016:
Comprehensive loss									(12,701	)		185			(12,516	)
Exercise of restricted share units		22,498		1		(1	)
Share-based compensation (Note 5c)						1,230									1,230
BALANCE AT JUNE 30, 2016		30,661,632	$	1,285	$	147,107		$	(58,931	)	$	55		$	89,516

FOAMIX PHARMACEUTICALS LTD.

CONSOLIDATED STATEMENTS OF CASH FLOWS
(U.S. dollars in thousands)

(Unaudited)

	Six months ended June 30
	2016			2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$	12,701		$	7,732
Adjustments required to reconcile loss to net cash used in operating activities:
Depreciation and amortization		66			77
Changes in marketable securities and bank deposits, net		242			67
Changes in accrued liability for employee severance benefits, net of retirement fund profit		14			28
Share-based compensation		1,230			859
Non cash finance income, net		(2	)		(43	)
Changes in operating asset and liabilities:
Decrease (increase) in trade and other receivable		(342	)		191
Increase (decrease) in accounts payable and accruals		(616	)		771
Net cash used in operating activities		(12,109	)		(5,782	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets		(216	)		(149	)
Investment in bank deposits		(13,000	)		(28,025	)
Investment in marketable securities		(700	)		(46,762	)
Proceeds from sale and maturity of marketable securities and bank deposits		27,725			6,028
Net cash provided by (used in) investing activities		13,809			(68,908	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of ordinary shares through a public offering, net of issuance costs		-			64,202
Proceeds from exercise of warrants		-			2,130
Proceeds from exercise of options		-			315
Payments in respect of BIRD loan		(476	)		-
Payments in respect of bank borrowings		(16	)		(16	)
Net cash provided by (used in) financing activities		(492	)		66,631

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		1,208			(8,059	)
EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS		3			7

CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD		18,795			43,008

CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	$	20,006		$	34,956

SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS

Cashless exercise of warrants		-			4

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for taxes		119			-
Interest received		641			-
Interest paid		239			-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

FOAMIX PHARMACEUTICALS LTD.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(U.S. dollars in thousands, except share and per share amounts)

NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION:

Nature of operations

Foamix Pharmaceuticals Ltd. (hereinafter “Foamix”) is an Israeli company incorporated in 2003. Foamix is a clinical-stage specialty pharmaceutical company operating in one segment - the development and commercialization of foam-based formulations, using its proprietary technology, which includes its foam platforms. Foamix develops its own product candidates, mainly for the treatment of moderate-to-severe acne and other skin conditions. It also licenses its technology under development and licensing agreements to various pharmaceutical companies for development of certain products combining Foamix's foam technology with the licensee’s proprietary drugs.

Since incorporation through June 30, 2016, Foamix and its subsidiary (hereinafter “the Company”) incurred losses and negative cash flows from operations mainly attributable to its development efforts and has an accumulated deficit of $58,931. The Company has financed its operations mainly through the issuance of shares through private and public financing rounds, convertible loans and payments received under development and licensing agreements. The Company's cash, cash equivalents, deposits and marketable securities as of June 30, 2016, will allow the Company to fund its operating plan through at least the next 12 months. However, the Company expects to continue to incur significant research and development and other expenses related to its ongoing operations and in order to continue its future operations, the Company will need to obtain additional funding until becoming profitable. If the Company is unable to obtain such funding it will need to curtail or cease operations.

Basis of presentation

The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") for interim financial statements. Accordingly, they do not contain all information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s consolidated financial position as of June 30, 2016, the consolidated results of operations and comprehensive loss for the three and six-month periods ended June 30, 2016 and 2015, the consolidated changes in shareholders’ equity and cash flows for the six-month periods ended June 30, 2016 and 2015.

These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual financial statements for the year ended December 31, 2015. The condensed consolidated balance sheet data as of December 31, 2015 was derived from the audited consolidated financial statements for the year ended December 31, 2015, but does not include all disclosures required by U.S. GAAP.

The results for the three and six-month periods ended June 30, 2016 are not necessarily indicative of the results expected for the year ending December 31, 2016.

FOAMIX PHARMACEUTICALS LTD.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(U.S. dollars in thousands, except share and per share amounts)

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:

Principles of consolidation

The consolidated financial statements include the accounts of Foamix and its subsidiary. Intercompany balances and transactions including profits from intercompany sales not yet realized outside the Company, have been eliminated upon consolidation.

Bank deposits

Bank deposits with original maturity dates of more than three months but less than one year are included in short-term deposits. Bank deposits with maturity of more than one year are considered long-term. The interest rates on the Company’s deposits range between 1.32%-1.6%. The fair value of bank deposits approximates the carrying value since they bear interest at rates close to the prevailing market rates.

Marketable securities

The Company invests in debt and equity securities classified as available for sale in accordance with ASC 320, Investments - Debt and Equity Securities.

Management determines the appropriate classification of its investments in securities at the time of purchase and reevaluates such determinations at each balance sheet date. Classifications of debt securities in the balance sheet are determined based on the maturity date of the securities.

Unrealized gains of available for sale securities, net of taxes, are reflected in other comprehensive income. Unrealized losses considered to be temporary are reflected in other comprehensive income; unrealized losses that are considered to be other-than-temporary are charged to income as an impairment charge. Realized gains and losses for both debt and equity securities are included in financial expense, net.

For equity securities, the Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost. For debt securities, an other-than-temporary impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in financial expense, net, is limited to the portion attributed to credit loss. The remaining portion of the other-than-temporary impairment related to other factors is recognized in other comprehensive income or loss.

Derivatives

The Company purchases foreign exchange derivative financial instruments (written and purchased currency options). The transactions are designed to hedge the Company’s currency exposure.

The Company recognizes all derivatives as either assets or liabilities in the consolidated balance sheet at their fair value. Changes in the fair value of derivatives that are highly effective and designated as cash flow hedges are reported as a component of other comprehensive income or loss and reclassified into earnings in the same line-item associated with the forecasted transaction and in the same periods during which the hedged transaction impacts earnings.

FOAMIX PHARMACEUTICALS LTD.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(U.S. dollars in thousands, except share and per share amounts)

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

For derivatives that qualify for hedge accounting, the cash flows associated with these derivatives are reported in the consolidated statements of cash flows consistently with the classification of cash flows from the underlying hedged items that these derivatives are hedging.

Newly issued and recently adopted accounting pronouncements:

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which impacts virtually all aspects of an entity’s revenue recognition. The core principle of Topic 606 is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In July 2015, the FASB deferred the effective date of the standard by one year which results in the new standard being effective for the Company at the beginning of its first quarter of fiscal year 2018. In addition, during March, April and May 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing and ASU 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, respectively, which clarified the guidance on certain items such as reporting revenue as a principal versus agent, identifying performance obligations, accounting for intellectual property licenses, assessing collectability and presentation of sales taxes. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

In January 2016, the FASB issued ASU No. 2016-01, "Financial Instruments—Overall (Subtopic 825-10)." This standard makes several modifications to Subtopic 825-10 including the elimination of the available-for-sale classification of equity investments, and requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income. It is effective for interim and annual periods beginning after December 15, 2017. The Company is currently evaluating the impact of the amended guidance on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

FOAMIX PHARMACEUTICALS LTD.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(U.S. dollars in thousands, except share and per share amounts)

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718). ASU No. 2016-09 identifies areas for simplification involving several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. The amendments are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted but all of the guidance must be adopted in the same period. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, “Measurement of Credit Losses on Financial Instruments.” This ASU significantly changes how entities will measure credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. In issuing the standard, the FASB is responding to criticism that today’s guidance delays recognition of credit losses. The standard will replace today’s “incurred loss” approach with an “expected loss” model. The new model, referred to as the current expected credit loss (“CECL”) model, will apply to: (1) financial assets subject to credit losses and measured at amortized cost, and (2) certain off-balance sheet credit exposures. This includes, but is not limited to, loans, leases, held-to-maturity securities, loan commitments, and financial guarantees. The CECL model does not apply to available-for-sale (“AFS”) debt securities. For AFS debt securities with unrealized losses, entities will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. As a result, entities will recognize improvements to estimated credit losses immediately in earnings rather than as interest income over time, as they do today. The ASU also simplifies the accounting model for purchased credit-impaired debt securities and loans. ASU 2016-13 also expands the disclosure requirements regarding an entity’s assumptions, models, and methods for estimating the allowance for loan and lease losses. In addition, entities will need to disclose the amortized cost balance for each class of financial asset by credit quality indicator, disaggregated by the year of origination. ASU No. 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019; early adoption is permitted for interim and annual reporting periods beginning after December 15, 2018. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (i.e., modified retrospective approach). The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial statements.

FOAMIX PHARMACEUTICALS LTD.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(U.S. dollars in thousands, except share and per share amounts)

NOTE 3 - FAIR VALUE PRESENTATION

Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:

Level 1:

Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2:

Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

Level 3:

Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.

The Company’s assets and liabilities that are measured at fair value as of June 30, 2016 and December 31, 2015 are classified in the tables below in one of the three categories described above:

	June 30, 2016
	Level 1			Level 2				Total
Marketable securities		$	954		$	41,803			$	42,757
Currency options designated as hedging instruments			-		$	17			$	17

	December 31, 2015
	Level 1			Level 2				Total
Marketable securities		$	1,977		$	54,770			$	56,747
Currency options designated as hedging instruments (current liability)			-		$	(5	)		$	(5	)

Foreign exchange risk management

The Company purchases and writes non-functional currency options in order to hedge the currency exposure on the Company’s cash flow. The currency hedged items are denominated in New Israeli Shekel (NIS). The purchasing and writing of options is part of a comprehensive currency hedging strategy. These transactions are at zero cost for periods of up to one year. The counterparties to the derivatives are major banks in Israel.

During February 2015, the Company began purchasing and writing options in respect of salary, rent and other expenses dominated in NIS for a period of up to a year ahead. These transactions qualify for cash flow hedge accounting. During the six months ended June 30, 2016 the Company recorded income in the amount of $4 in operating expenses relating to hedge transaction.

As of June 30, 2016 the total hedged amount was NIS 12.3 million.

As of June 30, 2016, the Company has a lien in the amount of $761 on the Company’s marketable securities in respect of bank guarantees granted in order to secure the hedging transactions.

FOAMIX PHARMACEUTICALS LTD.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(U.S. dollars in thousands, except share and per share amounts)

NOTE 4 - MARKETABLE SECURITIES

Marketable securities as of June 30, 2016 consist mainly of debt and equity securities. These securities are classified as available-for-sale and are recorded at fair value. Changes in fair value, net of taxes (if applicable), are reflected in other comprehensive loss. Realized gains and losses on sales of the securities, as well as premium or discount amortization, are included in the consolidated statement of operations as finance income or expenses.

The following table sets forth the Company’s marketable securities:

	June 30,		December 31,
	2016		2015

Israeli mutual funds	$	954	$	1,977
Certificates of deposit		28,126		35,627
Municipal and agency bonds		13,677		19,143
Total	$	42,757	$	56,747

As at June 30, 2016 and December 31, 2015 the fair value, cost and gross unrealized holding gains of the securities owned by the Company were as follows:

	June 30, 2016
	Fair value		Cost or Amortized cost		Gross unrealized holding losses		Gross unrealized holding gains
Israeli mutual funds	$	954	$	952		-	$	2
Certificates of deposit		28,126		28,096		4		34
Municipal and agency bonds		13,677		13,671		2		8
Total	$	42,757	$	42,719	$	6	$	44

	Market value
	June 30, 2016		December 31, 2015
Due within one year	$	27,203	$	22,485
1 to 2 years		12,288		27,046
2 to 3 years		2,312		5,239
Total	$	41,803	$	54,770

	Six month ended June 30,
	2016
	Award amount		Exercise price range		Vesting period	Expiration
Employees:
Options		615,310	$	6.04-$6.66	4 years	10 years
RSUs		5,000		-	4 years		-

Consultants -
options		4,800	$	6.34	4 years	10 years

	Six month ended June 30,
	2015
	Award amount		Exercise price range		Vesting period	Expiration
Employees -
options		153,000	$	6.77	4 years	10 years
RSUs		189,000		-	4 years		-

Directors-
options		24,000	$	11.87	3 years	10 years

Consultants -
RSUs		83,000		-	4 years		-

	Six months ended June 30
	2016			2015
Value of ordinary share	$	5.90-$6.84		$	7.53-$11.99
Dividend yield		0	%		0	%
Expected volatility*		60.3%-60.5	%		63.4%-64.9	%
Risk-free interest rate		1.36%-1.52	%		1.38%-1.98	%
Expected term	6 years			6 years

	June 30, 2016
Value of ordinary share	$	6.52
Dividend yield		0	%
Expected volatility*		69.2	%
Risk-free interest rate		1.78	%
Expected term	10 years

2016	$	155
2017		613
2018		554
2019 and thereafter		1,112
Total	$	2,434